Navigation Links
A Drug That Carries a Lower Risk of Weight Gain Than AstraZeneca's Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
Date:4/22/2008

Seroquel's Successor, Seroquel XR, Will Earn a 16 Percent Patient Share in

the Bipolar Disorder Market by 2016, According to a New Report from

Decision Resources

WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that carries a lower risk of weight gain than AstraZeneca's Seroquel and has both antimanic and antidepressant effects would earn a 30 percent patient share in the treatment of bipolar disorder, according to surveyed psychiatrists.

The new report entitled Bipolar Disorder: Although Bipolar Mania Is a Crowded Market, Physicians Continue to Demand Better Treatment finds that surveyed psychiatrists indicate that they would prescribe AstraZeneca's Seroquel XR to 20 percent of their bipolar disorder patients, following its approval for the indication in 2009. As a result, Seroquel XR is forecasted to earn a 16 percent patient share in the U.S. bipolar disorder market in 2016.

The report also finds that Seroquel XR will earn gold-standard status for treatment of bipolar disorder in 2011 as interviewed psychiatrists indicate that Seroquel XR's delivery profile -- once-daily dosing -- will be marginally superior to that of Seroquel immediate-release. Although surveyed psychiatrists indicated that lithium and Eli Lilly's Zyprexa have advantages in efficacy, lithium and Zyprexa have disadvantages in safety, tolerability and/or delivery when compared to Seroquel.

"Interviewed psychiatrists report that Seroquel can sometimes require twice-daily dosing for sustained efficacy," said Kate Hohenberg, director at Decision Resources. "As a result, Seroquel XR narrowly edges out its parent compound to become the new gold standard because of its incremental advantage in delivery."

About the Report

Bipolar Disorder: Although Bipolar Mania Is a Crowded Market, Physicians Continue to Demand Better Treatment is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Obesity During Pregnancy Carries Bigger Price Tag
2. Survival rates appear lower for scalp and neck melanoma than for other sites
3. Hospital Care in Singapore Now Available to American Patients at Pre-Negotiated, In-Network Rates Far Lower than Comparable Services in the U.S.
4. Bioponic Phytoceuticals Announces Curecumin(TM) May Lower Heart Failure Risk
5. AUDIO from Medialink and Apple Products Research and Education Council: New Research -- Adults Who Eat Apples, Apple Juice Have Healthier Diets and Lower Risk for Metabolic Syndrome
6. Risk of Womens Heart Attack or Stroke Appears to Be Lowered by DASH Diet
7. Blocking the effect of inflammation-causing cells lowered prostate cancer cells invasion
8. Adults who eat apples, drink apple juice have lower risk for metabolic syndrome
9. Medco Acquires Majority Interest in Europa Apotheek; Delivering Innovation, Clinical Quality and Lower-Cost Solutions to Fast-Growing German Health Care Market
10. Lowering Blood Pressure Improves Brain Hemorrhage Outcomes
11. Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: